Videos and Podcasts

4th May 21

Pharmaxis drug to be focus of new brain cancer study with grant from Charlie Teo Foundation

Pharmaxis Ltd's (ASX:PXS) (FRA:UUD) CEO Gary Phillips tells Proactive's Andrew Scott its drug PXS-5505 will be the focus of a new study, funded by a grant from the Charlie Teo Foundation, looking at an aggressive and deadly form of brain cancer. The drug, which has commenced a phase 1/2a clinical trial for the rare bone marrow cancer myelofibrosis, will now enter pre-clinical efficacy testing for glioblastoma (GBM), the most common form of brain cancer with an average survival of only 15 months from diagnosis.

Watch the interview here.

6th Apr 21

Pharmaxis CEO Gary Phillips details world-first clinical trial of treatment to prevent wound and burn scars

Pharmaxis Ltd CEO Gary Phillips speaks to Proactive's Andrew Scott soon after announcing they've entered a world-first clinical trial aiming to stop scars forming after trauma - particularly following burn injuries. Distinguished surgeon and burns expert Professor Fiona Wood AM is leading a group of researchers from the University of Western Australia (UWA) and Fiona Stanley Hospital to test the treatment in the first human trials.

Watch the interview here.